Our study enrolled patients who were newly diagnosed diabetes during 2010 to 2011, when neither SGLT2i (Dapagliflozin, Empagliflozin, Canagliflozin) nor GLP1-RAs (Liraglutide, Dulaglutide, Semaglutide) with proven benefit in renal outcome were available in Korea. The gene discussed is GLP1R; the disease is diabetes mellitus.